These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 1298959)

  • 1. [Polymorphism of acetylation and oxidation phenotypes and the risk of neoplasms--pharmacogenetic approach to the epidemiology of neoplasms].
    Mrozikiewicz PM
    Postepy Hig Med Dosw; 1992; 46(5):531-6. PubMed ID: 1298959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The acetylation and oxidation phenotypes in insulin-dependent diabetes mellitus.
    Mrozikiewicz A; Kiełczewska-Mrozikiewicz D; Lowicki Z; Chmara E; Mrozikiewicz PM; Jabłecka A; Kaźmierczak E; Andrys I
    Mater Med Pol; 1995; 27(4):147-9. PubMed ID: 9000838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic polymorphism of drug metabolism.
    Paxton JW
    N Z Med J; 1984 Aug; 97(762):567-9. PubMed ID: 6591031
    [No Abstract]   [Full Text] [Related]  

  • 5. [N-acetyltransferase genetic polymorphism and its role in the development of neoplastic disease].
    Lutz W
    Med Pr; 2000; 51(3):277-84. PubMed ID: 11002474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oxidative phenotype as a marker of individual predisposition to neoplasm induced by chemical carcinogens.
    Lutz W; Sułkowski W
    Pol J Occup Med; 1990; 3(3):257-72. PubMed ID: 2136533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of genetically determined oxidation of drugs and xenobiotics in pathogenesis of neoplastic diseases].
    Niewiński P; Orzechowska-Juzwenko K
    Postepy Hig Med Dosw; 1996; 50(4):321-32. PubMed ID: 9019742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Stability and/or variability of the expression of genetic polymorphism of hydroxylation and acetylation in patients with various pathologies and under various treatments].
    Bechtel P; Joanne C; Bechtel Y; Grandmottet M; Jounet JM
    Ann Biol Clin (Paris); 1986; 44(4):361-7. PubMed ID: 3538951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biotransformation of phenazone and sulfadimidine as markers of liver metabolism of drug and xenobiotic oxidation and acetylation in women with breast cancer].
    Orzechowska-Juzwenko K; Wiela-Hojeńska A; Milejski P; Cieślińska A; Hudziec P; Adamska M
    Przegl Lek; 1997; 54(2):103-6. PubMed ID: 9198818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetically hazardous drugs: a proposed new scoring method.
    Szórády I; Sánta A
    Acta Physiol Hung; 1991; 77(3-4):305-18. PubMed ID: 1755332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphic NATs and cancer predisposition.
    Hirvonen A
    IARC Sci Publ; 1999; (148):251-70. PubMed ID: 10493262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility.
    Badawi AF; Stern SJ; Lang NP; Kadlubar FF
    Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Genetic polymorphism of the hepatic metabolism of drugs].
    Larrey D; Pessayre D; Benhamou JP
    Gastroenterol Clin Biol; 1985; 9(6-7):522-31. PubMed ID: 3926587
    [No Abstract]   [Full Text] [Related]  

  • 15. [Importance of genetically determined acetylation of drugs and xenobiotics in pathogenesis of neoplasms].
    Niewiński P; Orzechowska-Juzwenko K
    Pol Merkur Lekarski; 1997 Jan; 2(9):231-5. PubMed ID: 10907039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic polymorphisms of oxidation and acetylation in cancers of digestive system].
    Barańska M; Skretkowicz J
    Pol Merkur Lekarski; 2009 Feb; 26(152):145-7. PubMed ID: 19388522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of susceptibility and environmental cancer risk: experiences in Italy.
    Landi MT
    Med Lav; 1995; 86(3):214-21. PubMed ID: 7565280
    [No Abstract]   [Full Text] [Related]  

  • 18. Aromatic and heterocyclic amine metabolism and phenotyping in humans.
    Lang NP; Kadlubar FF
    Prog Clin Biol Res; 1991; 372():33-47. PubMed ID: 1956928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of phenazone oxidation and sulfadimidine acetylation in patients with hematologic neoplasms].
    Wiela-Hojeńska A; Milejski P; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Urbaniak-Kujda D; Kotlarek-Haus S
    Przegl Lek; 1997; 54(3):163-6. PubMed ID: 9297191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
    Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
    Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.